Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults

Seasonal Influenza B Clinical Trial

Official title:

Phase 1 , Placebo-Controlled, Dose-Ranging Trial to Determine Safety and Immunogenicity of an Oral Adenoviral-Vector Based Influenza B Vaccine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02547792
• Other study ID #: VXA03-001
• Status: Completed
• Phase: Phase 1
• Start date: October 20, 2015
• Est. completion date: November 21, 2016

Study information

• Verified date: May 2018
• Source: Vaxart
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 1, single-center, placeb-controlled, double-blind study. The purpose of this study is to determine the safety and immunogenicity of an oral vaccine tablet to prevent seasonal influenza B tested at two dose levels (low and high dose). The study will enroll 27 subjects in the low dose cohorts (3 sentinel open label subjects followed by 24 subjects (randomized 2:1 to vaccine vs placebo, respectively). Subsequently, 27 subjects will be enrolled in the high dose cohort in a similar manner as to the low dose cohort. Safety and immunogenicity will be evaluated at Day 28. Long term safety follow-up will be evaluated through 1 year post vaccination.

Description:

The study will enroll 54 subjects in four cohorts. All subjects will receive a single administration of VXA-BYW.10 at a low dose, a high dose or placebo.

Two sentinel groups will enroll 3 subjects each in an open-label manner (Cohorts 1 and 3) to receive VXA-BYW.10 prior to enrolling either of the randomized, controlled cohorts (Cohorts 2 and 4). Within the double-blinded Cohorts (2 and 4), placebo subjects will receive the same number of tablets as the vaccine subjects in that Cohort. Subjects will be enrolled and dosed in the low dose groups prior to initiation of dosing in the high dose group.

Cohort 1: 3 subjects at low dose; Cohort 2: 16 subjects at low dose and 8 placebo; Cohort 3:

3 subjects at high dose; Cohort 4: 16 subjects at low dose and 8 placebo

Subjects will be followed for 28 days post vaccination for preliminary immunogenicity. Subjects will continue to be followed for 1 year post-vaccination for long term safety.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 54
• Est. completion date: November 21, 2016
• Est. primary completion date: November 21, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 49 Years

Eligibility

Inclusion Criteria:

• In good health as established by medical history, physical examination, and laboratory testing at the time of enrollment.

Exclusion Criteria:

• Positive for B influenza by HAI.

• Has had an influenza vaccine in the past 2 years.

• Current history of chronic alcohol use and/or illicit and/or recreational drug use.

• History of any confirmed or suspected immunodeficient or immunosuppressive condition

• Positive serology for HIV, HCV, or HBV

• Previous serious reactions to vaccination such as anaphylaxis, respiratory problems, hives, or abdominal pain.

• History of irritable bowel disease or other inflammatory digestive or gastrointestinal conditions that could affect the intended distribution of the vaccine targeting the mucosa of the small intestine

• Use of proton pump inhibitors(Nexium, Prilosec).

• Stool sample with occult blood at baseline exam

• Pregnancy

Related Conditions & MeSH terms

• Influenza, Human
• Seasonal Influenza B

Intervention

Biological:
• VXA-BYW.10 (Low Dose) Oral Vaccine
Enteric coated tablet for oral delivery
• VXA-BYW.10 (High Dose) Oral Vaccine
Enteric coated tablet for oral delivery

Other:
• Placebo Tablets
Enteric coated tablet for oral delivery

Locations

Country	Name	City	State
New Zealand	CCST	Christchurch

Sponsors (1)

Lead Sponsor	Collaborator
Vaxart

Country where clinical trial is conducted

New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and Tolerability of Single High Dose of an Oral Influenza B Tablet Vaccine	Safety determined by reported solicited (reactogenicity) and unsolicited AEs.	Day 28
Secondary	Immunogenicity of Single high Dose of an Oral Influenza B Tablet Vaccine	Efficacy determined by HAI titers at Day 28 post-vaccination	Day 28